Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects

Completed · Phase 2 · Has a placebo group

Conditions studied: Hepatitis C, Chronic

In brief

GSK2336805 is a hepatitis C virus (HCV) NS5A inhibitor being developed for the treatment of chronic hepatitis C (CHC). This study will assess the safety, antiviral activity, and pharmacokinetics of GSK2336805 alone and in combination with peginterferon alfa 2a and ribavirin in subjects with chronic hepatitis C (CHC).

Key facts

Study ID

NCT01439373

Run by

GlaxoSmithKline

People needed

16

Starts

2011-07-07

Expected to finish

2011-12-05

Last updated by the study team

2017-12-11

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

Where it is running

• GSK Investigational Site — Anaheim, California, United States
• GSK Investigational Site — Chula Vista, California, United States
• GSK Investigational Site — Coronado, California, United States
• GSK Investigational Site — La Mesa, California, United States
• GSK Investigational Site — Oceanside, California, United States
• GSK Investigational Site — Miramar, Florida, United States
• GSK Investigational Site — Las Vegas, Nevada, United States
• GSK Investigational Site — Tulsa, Oklahoma, United States
• GSK Investigational Site — Houston, Texas, United States
• GSK Investigational Site — San Juan, Puerto Rico

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.